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SEK. ConClusions: Given a willingness-to-pay threshold of 600,000 SEK/QALY, 
posaconazole is likely to be cost-effective for preventing IFIs in GVHD-patients 
compared to fluconazole.
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EcoNomIc EvaluatIoN of uNIvErsal aNtENatal HIv scrEENINg 
comParEd wItH currENt “at rIsk” PolIcy IN IsraEl
Chowers M.1, Shavit O.2
1Meir Medical Center, Kfar Saba, Israel, 2Meuhedet Health Fund, Tel-Aviv, Israel
Israeli ministry of health guidelines for antenatal screening recommend HIV test-
ing only in women belonging to high risk groups. This policy resulted in the last 
10 years in an annual average of two infected children from unidentified Israeli 
women. objeCtives: To evaluate an alternative strategy of universal screen-
ing using a cost utility analysis. Methods: A budget impact analysis was first 
conducted to evaluate the cost of introducing universal screening using a payer 
perspective. Following, a cost-utility analysis (CUA) was carried out to evaluate 
long term effects of such strategy, compared with current policy. The model was 
comprised of two steps: a decision tree simulating the period from pregnancy 
to delivery and a successive Markov model simulating life expectancy of the 
newborn. Screening test sensitivity and specificity were regarded as 99.94% and 
99.5% respectively. Probabilities for having HIV for the low and high-risk popula-
tions were based on experts’ opinion. They were then adjusted to allow model 
calibration to reflect real-life finding as presented above. The cost of the screen-
ing test was US$ 5.5. Other costs included physician visits, viral load and blood 
tests, CD4 counts, and medications. QALY weights were 0.83 for HIV and 0.7 for 
AIDS. Results: Probabilities for having HIV for the low and high-risk populations 
were 0.0215% and 1% respectively. The incremental cost of the universal screening 
over current policy for an annual cohort of 166,000 Israeli pregnant women was 
US$1 million, reflecting a cost of $500,000 per a case of an HIV+ baby avoided. For 
this cohort, an incremental 18 QALYS were projected over a 90 year time hori-
zon with an incremental cost-effectiveness ratio of US$ -30,000. ConClusions: 
Universal Antenatal HIV screening should be implemented in Israel. The current 
policy of screening identified high-risk women is both less effective and more 
costly.
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HEaltH EcoNomIcs assEssmENt of rIlPIvIrINE vErsus comParators as 
fIrst-lINE aNtIrEtrovIral tHEraPIEs IN HIv-1 PatIENts wItH a vIral 
load (vl) ≤ 100,000 coPIEs/ml IN fraNcE
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objeCtives: In France, rilpivirine is reimbursed for HIV-1-infected treatment-
naïve patients with VL≤ 100,000 copies/mL for whom the use of efavirenz is not 
appropriate. This analysis aims to compare costs and outcomes of rilpivirine vs. 
other third antiretroviral (ARVs) agent recommended in France (in addition to two 
NRTIS). Methods: A cohort-based Markov model with four therapy lines and six 
health states based on CD4+ cell-count ranges was developed based on 1-year 
cycle and a 5-year time horizon. First-line efficacy data at 48 and 96 weeks was 
first assumed to be similar across treatments, and subsequently set to statisti-
cally significantly different (SSD) values from phase-III trial analyses of patients 
with VL≤ 100,000 copies/mL. Costs of first-line treatments were obtained from the 
French National Formulary. Costs associated with subsequent treatments and 
CD4+ health states were derived from a French cost-effectiveness analysis. Other 
clinical inputs, HIV-related mortality rates and utility were derived from inter-
national publications. Outcomes and costs were discounted at 4%. Robustness 
of results was assessed using sensitivity analyses (e.g. using efficacy values 
no SSD). Results: All phase-III trials (i.e. ECHO/THRIVE, STARTMRK, CASTLE, 
ARTEMIS, KLEAN, GEMINI, 2NN) demonstrated a non-inferior antiviral efficacy 
between arms. In patients with VL≤ 100,000 copies/mL, response rates were avail-
able for rilpivirine (1-year: 90,2%; 2-year: 84,0%), ritonavir-boosted (/r) darunavir 
(1-year: 79,5%; 2-year: 76,1%), lopinavir/r (1-year: 84,5%; 2-year: 75,2%), atazanavir/r 
(1-year: 82%; 2-year: 75%), fosamprenavir/r (1-year: 67%) and raltegravir (1-year: 
93%). CD4+ cell count changes per mm3 were available for atazanavir/r (1-year: 
+179; 2-year: +243), lopinavir/r (1-year: +194; 2-year: +267), rilpivirine (1-year: +185) 
and raltegravir (1-year: +180). Rilpivirine was the less expensive option in the cost-
minimisation analyses and dominated all treatments in the cost-effectiveness 
analyses when considering SSD efficacy values. ConClusions: The analysis pro-
vided health economic results for HIV-1-infected treatment-naïve patients with 
VL≤ 100,000 copies/mL favoring rilpivirine over all other ARVs analysed.
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objeCtives: To assess the cost-effectiveness of telaprevir (TVR) added to peginter-
feron and ribavirin (PR) therapy in treatment naive (TN) and experienced (TE) 
genotype 1 chronic HCV patients in Poland. Methods: Analysis was based on 
a previously validated Markov model, describing the progression of the disease 
over a lifetime, adapted to population characteristics specific to Poland and cost 
parameters obtained via questionnaire studies completed by clinical practition-
ers. The model comprises the following health states: mild CHC without/with 
SVR (remission), moderate CHC without/with SVR, cirrhosis without/with SVR, 
antiviral therapy, decompensated cirrhosis, HCC, liver transplantation, post-liver 
transplant, CHC related death. The following treatment strategies were considered: 
PEG++ RBV therapy for 48 weeks; TVR for 12 weeks with PEG+RBV (response-guided 
therapy in TN and 48 weeks in TE patients). A cost-utility analysis was conducted 
goal of this study was to perform economic evaluation of maraviroc compared with 
other new antiretroviral agents, such as raltegravir, darunavir and enfuvirtide for 
treatment-experience patients with HIV infection in Russia. Methods: Indirect 
comparison was performed to assess the relative clinical efficacy and safety of 
compared drugs, all in combination with optimized background therapy (OBT). 
A mathematical model was created in Microsoft Excel software to estimate the 
direct medical costs of: compared drugs, an average OBT regimen and routine 
outpatient follow-up (including visits to specialists and diagnostic tests). Drug 
and medical services cost calculations were based on registered prices from the 
list of vital and essential drugs and financial standards of regional program of 
national guarantees for the provision of free medical care to Russian citizens in 
Moscow in 2012, respectively. The obtained results were tested in sensitivity analy-
sis. Results: According to indirect comparison results, there were no statistically 
significant differences between maraviroc, raltegravir, darunavir and enfuvirtide 
neither by the undetectable HIV RNA level nor CD4(+) cell-count changes. The rate 
of adverse events was comparable (except enfuvirtide that has more injection-site 
reactions). Maraviroc-containing regimen compared with raltegravir-, darunavir- 
and enfuvirtide-containing regimen is associated with reduced costs and saves 
an average 177 764.16 rub (€ 4 209.94), 59 929.92 rub (€ 1 419.30) and 462 295.92 rub 
(€ 10 948.42) per 48 weeks of therapy, and 340 714.64 rub (€ 8 069.05) and 114 865.68 
rub (€ 2 720.33) and 886 067.18 rub (€ 20 984.47) per 96 weeks of therapy per patient, 
respectively. Results were robust in one-way sensitivity analyses. ConClusions: 
The analysis showed that maraviroc compared with darunavir, raltegravir and 
enfuvirtide is a cost-saving treatment option for CCR5 tropic treatment-experi-
enced patients in Russia.
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objeCtives: The addition of boceprevir (BOC) to peginterferon–ribavirin (PR) 
resulted in significantly higher rates of sustained virologic response in naive or 
pretreated patients with the chronic hepatitis C virus (HCV) genotype 1 infection, as 
compared with PR alone. The objective is to project the long-term clinical benefits 
and estimate the cost-effectiveness of the treatment strategies recommended in 
the BOC label compared with PR alone. Methods: A Markov model was created 
to estimate the expected costs and quality adjusted life-years (QALYs) associated 
with the BOC tritherapy and PR. The model simulates the treatment regimens and 
the natural history of the chronic HCV to project the lifetime cumulative incidence 
of advanced liver-related diseases (decompensated cirrhosis (DC), hepatocellular 
carcinoma (HCC)) and liver transplant. Series of 30 cohorts representing all com-
binations of pre-specified patient characteristics progress through the model. The 
baseline characteristics used to define the cohorts are: naive/pretreated, age, gender, 
baseline fibrosis score and race cohort for the treatment naive population only. 
Separate analyses were run for naive and pretreated patients. The distribution of 
baseline fibrosis score for each analysis was based on the subjects enrolled in the 
clinical trials; the average age and distribution of race cohort were based on French 
observational study (F. Roudot Thoraval, ADEQUATION, AFEF 2009). The comparator 
was PR (48 weeks). Results: The model predicted relative reductions in patients 
treated with BOC vs PR alone: 33% and 32% in DC/HCC in naive patients and also 
46% and 53% in DC/HCC in pretreated patients. The ICER of BOC-based therapy 
compared with PR were 15,681€ /QALY for naive patients and 10,563€ /QALY for pre-
treated patients. ConClusions: Compared with PR, boceprevir-based treatment is 
projected to substantially reduce the burden of liver complications associated with 
the chronic hepatitis C virus genotype 1 and is highly cost-effective if a threshold 
of 50,000€ /QALY is assumed.
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cost-utIlIty aNalysIs of PosacoNazolE vErsus flucoNazolE for 
PrEvENtIoN of INvasIvE fuNgal INfEctIoNs IN PatIENts wItH graft-
vErsus-Host dIsEasE IN swEdEN
Lundberg J.G.1, Jensen A.V.1, Bjorkholm M.2, Hoglund M.3, Akerborg O.4
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objeCtives: In allogeneic transplant (allo-SCT) recipients with graft-versus-host 
disease (GVHD) the risk of contracting an invasive fungal infection (IFI) is high and 
antifungal prophylaxis to prevent IFIs is routinely given. Fluconazole, has been 
standard antifungal prophylaxis in GVHD-patients in Sweden. Recently many 
Swedish centers have switched from fluconazole, which lacks efficacy against 
Aspergillus, to posaconazole, for the prevention of IFIs in GVHD-patients receiving 
moderate to high doses of glucocorticoids. Although, the superior efficacy of posa-
conazole vs. fluconazole in preventing IFIs have been demonstrated in this clinical 
setting, the cost-effectiveness of posaconazole vs. fluconazole for GVHD-patients in 
Sweden has not been established. The aim of this analysis is to estimate the cost-
effectiveness of posacoanzole vs. fluconazole prophylaxis in allo-SCT recipients 
with severe GVHD receiving immunosuppressive therapy in Sweden. Methods: 
A decision-analytic model was used to determine life-time outcomes of patients 
with GVHD at high risk of contracting IFIs. The model outcomes were quality 
adjusted life years (QALYs), costs associated with IFI-prophylaxis and treatment 
of IFIs and the incremental cost-utility ratio. The efficacy data were gathered from 
a clinical trial comparing posaconazole with fluconazole prophylaxis in patients 
with GVHD. The resource use for treatment of IFIs was gathered by expert opin-
ion. Utility, mortality and unit costs were gathered from the literature. To assess 
the uncertainty of the modeled outcomes a probabilistic sensitivity analysis (PSA) 
was developed. Results: The incremental cost-utility ratio of posaconazole vs. 
fluconazole for the prevention of IFI in GVHD-patients in Sweden was 541,628 SEK/
QALY. The PSA showed a 56.4% probability for a cost per QALY less than 600,000 
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observational studies also confirmed the indirect protection provided by rota-
virus vaccination in countries where rotavirus vaccination programmes have 
been introduced. France has not yet implemented such a programme. Previously 
reported models in France do not include herd protection, thus underestimat-
ing the effectiveness of vaccination. Our study uses a dynamic transmission 
model to account for herd protection and therefore better predict the effect of 
an oral rotavirus pentavalent vaccination programme in France. Methods: 
We developed a dynamic model to account for susceptibility of rotavirus infec-
tion as a function of both age and the number of previous infections. It was 
parameterized with French data on rotavirus gastro-enteritis (RVGE) incidence 
and age-specific contact rates. We evaluated the direct and indirect effects of 
vaccination on disease incidence and clinical outcomes. A three-dose vaccine 
course was assumed to be administered to 75% of infant annually. Results: 
Our model predicts that vaccination can reduce the burden of RVGE by 66% in the 
four years following vaccine introduction, gradually increasing to 73% in the long 
term for children under 5 years of age. Our calculations show that herd immunity 
accounts for 11% to 20% of the overall RVGE reduction in children. Incidence in 
the unvaccinated adult population would also be reduced by more than 40% 
through herd protection. Vaccination is also predicted to reduce pressure on the 
health care system with the model estimating an annual reduction of 84% and 
82% in the number of hospitalization/nosocomial and outpatient visits for RVGE 
respectively. ConClusions: The use of dynamic models is critical to account 
for the indirect effects of rotavirus vaccination via herd protection and thus for 
policymakers to understand the true effectiveness of a country-wide rotavirus 
vaccination programme.
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costs assocIatEd wItH cold cHaIN usEd to storE aNd traNsPort 
tHErmally uNstaBlE aNtIrEtrovIral drugs
Omelyanovsky V.1, Fedyaeva V.K.2
1The Russian Presidential Academy of National Economy and Public Administration, Moscow, 
Russia, 2Fund for the Development of Social Policy and Health Care “Helios”, Moscow, Russia
objeCtives: In Russia free access to high quality health care for patients with 
AIDS and HIV infections guaranteed by state. Some antiretroviral (ARV) pharma-
ceuticals need to be transported and stored in special cold chain conditions that 
significantly increase the burden on the state budget. Use of thermally stable 
formulation if available may be efficient due to fewer expenses for cold chain pro-
vision. To estimate the costs associated with the cold chain conditions in Russian 
health care. Methods: We calculated the difference in costs associated with 
ARV drug lopinavir+ritonavir thermally stable and unstable form transporting 
and storage. Thermally unstable form requires cold chain conditions that drives 
the cost difference. Costs for additional equipment, electricity, staff salaries 
were estimated.We used prices and tariffs that were valid in 2011. Calculations 
were based on the assumption that all eligible registered HIV-infected patients 
in all regions of Russia receive lopinavir+ritonavir, the number of patients was 
extracted from state statistics for 2011with a forecast for 2012. Results: The 
difference in annual total costs of shipping toregional centers and storage till the 
moment patient gets the drug between thermally unstable and thermally stable 
form is 820,000 Euro. ConClusions: Choice of thermally stable form of ARV drug 
lopinavir+ritonavir which do not require cold chain conditions of transportation 
and storage can reduce the economic costs associated with the treatment of HIV 
infection in Russian health care.
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rE-EstaBlIsHINg tHE socIEtal valuE of PEdIatrIc comBINatIoN 
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objeCtives: Over the past decades, the number of vaccinations recommended 
for infants has increased significantly, in an effort pursuing wider protection 
against severe infectious diseases. In their first year, infants would typically get 
more than 50 injections. The use of combination vaccines provides one solution 
to the problem of high injection burden but may be undervalued due to the 
underestimation of vaccine-preventable diseases’ seriousness and vaccination 
benefits. Our objective is to investigate the societal value of pediatric combina-
tion vaccines. Methods: A literature search was performed using MEDLINE for 
relevant articles from 1990 to today, focusing on industrialized countries. A grey 
literature search on public health websites was used to complement the peer-
reviewed literature. Results: A total of 86 articles, of which 34 from the peer-
reviewed literature, met the inclusion criteria and were analyzed. Many articles 
presented qualitative argumentation but no quantitative evidence. Public health 
benefits included improved compliance, timeliness and vaccination coverage 
thanks to reduced injections and better acceptability by parents. Economic ben-
efits were linked to the improvement of daily practice efficiency through reduced 
administration burden (less visits, simplified record-keeping, handling, inventory 
management) and less administration-related errors such as the need for fewer 
syringes reducing risk of needle-stick injury. Combination vaccines could also 
enhance efficiency at health care system-level through reduced costs of trans-
port, cold chain, storage and wastage. ConClusions: This review supports the 
broader value of pediatric combination vaccines which may plausibly generate 
time and money savings in the short and longer term, and enhance efficiency at 
both micro and macro levels in the health care system. Findings often stemmed 
from US settings, the portability to other industrialized countries being therefore 
plausible but subject to some uncertainty. While there is a paucity of quantitative 
data to support these arguments, they have significant economic implications 
and warrant further investigation in future economic evaluations of pediatric 
combination vaccines.
to calculate the incremental cost-utility ratio (ICUR) for triple therapy. A subgroup 
analysis was conducted to evaluate cost-effectiveness of TN patients with IL28B 
T/T; Scheuer ≥ 2 and in TE patients with Scheuer ≥ 2. Results: In the overall 
TN population, ICUR is 80917 PLN/QALY (»€ 19736/QALY). ICURs in IL28B T/T and 
Scheuer ≥ 2 subgroups were 42407 PLN/QALY (»€ 10343/QALY) and 86984 PLN/
QALY (»€ 21216/QALY), respectively. In the overall TE population, ICUR is 81793 
PLN/QALY (»€ 19950/QALY). For Scheuer ≥ 2 subgroup ICUR = 72448 PLN/QALY 
(»€ 17670/QALY). Calculated values are below the cost-effectiveness threshold of 
105801 PLN/QALY (»€ 25805/QALY) in Poland. Results for relapsers, partial respond-
ers and null responders are also presented. ConClusions: Based on the cost-
utility analysis, telaprevir combination therapy is cost-effective compared to PR 
alone in Polish settings.
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comParatIvE costs aNalysIs of coNvENtIoNal stratEgy vErsus stEP-
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objeCtives: To estimate the cost difference between use and absence of use of 
Step-Down Strategy (SDS) with linezolid for treatment of nosocomial pneumonia 
(NP) caused by Gram Positive Bacteria (GPB) in Mexico, from public health care 
institution perspective. Methods: To evaluate the potential cost savings between 
the two strategies, a microcosting was made along three phases: (1) characteriza-
tion of therapeutic protocol, (2) assessment of resources and (3) estimation of the 
unit costs of medical care. The temporal horizon of the analysis was set to 14 days. 
Costs were estimated for the year 2013, expressed in US$ and consider the follow-
ing medical services: days of hospitalization, consultation with specialists, route of 
administration, laboratory and imaging tests as well as outpatient control, based 
on unit costs by level of care reported by Instituto Mexicano del Seguro Social. The 
frequency of use of these resources were determined from Delphi method with 
a panel of 10 experienced infectologists. We calculated the differences between 
average total costs (ATC). The stastistical significance difference between strate-
gies was evaluated by Student’s t statistic. Results: The ATC of patients using 
SDS was $10,116, [95%CI $9,344.6 - $10,887.3] and the ATC of patients not using 
this strategy was $17,251.6 [$16,379.4 - $18,123.8]. The average potential savings 
due the use of SDS over conventional therapy (only intravenous) are $ 7,135.6, 
(p< 0.001). ConClusions: The use of step down strategy could significantly 
reduce the costs of treatment of NP in terms of hospitalization, physician visits, 
laboratory and imaging tests, and drug administration, not as well the resources 
used in the outpatient control. In a challenging setting of cost containment poli-
cies, the use of step down strategy in suitable patients represents the opportunity 
to invest health care resources in a more efficient way.
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objeCtives: Vancomycin and linezolid are amongst the most commonly pre-
scribed antibiotics for hospital-acquired infections in China. The aim of this study 
is to estimate and compare the baseline characteristics, hospitalization costs, 
length of stay (LOS), length of therapy (LOT) and all-cause in-hospital mortality 
of patients treated with vancomycin or linezolid. Methods: Data were extracted 
from the electronic medical records (EMR) of a tertiary hospital in Shanghai (bed 
size 1700). The analysis included patients admitted for any underlying cause 
who received either vancomycin or linezolid between January 2009 and July 2012. 
Continuous variables were compared with t test and chi-square for categorical 
variables. Results: Of the total 3234 patients identified, 93.6% were treated with 
vancomycin (female: 40.6%, mean age: 55.8 years) and 6.4% were treated with 
linezolid (female: 22.2%, mean age: 62.3 years). Cardiac Surgery was the most 
frequent admitting department for the both groups, while cardiovascular disease 
was the top admission reason for the vancomycin group and pulmonary infec-
tion for the linezolid group. The average daily dose was 1.6±1.1 g for vancomycin 
and 1.2±0.5 g for linezolid. The all-cause in-hospital mortality was lower in the 
vancomycin group compared to the linezolid group (4.2% vs. 21.7%, p< 0.001). The 
vancomycin group had shorter LOS and LOT compared to the linezolid group 
(23.6±24.4 vs. 37.1±40.8 days, p< 0.001; 7.0±8.8 vs. 8.7±10.6 days, p= 0.025). The van-
comycin group had lower total hospitalization costs, medication costs and antibi-
otics costs compared to the linezolid group (RMB 68788±64956 vs. 125425±117055, 
p< 0.001; 33258±39792 vs. 70372±69115, p< 0.001; 15206±18957 vs. 34681±33184, 
p< 0.001). ConClusions: Vancomycin was more frequently prescribed than lin-
ezolid and was more likely to be used in females and younger patients. When 
compared to those patients treated with linezolid, vancomycin treatment was 
associated with a shorter LOS and LOT, decreased total hospitalization costs and 
decreased total medication and antibiotics costs.
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wHat clINIcal BENEfIts could BE EXPEctEd from tHE ImPlEmENtatIoN 
of a rotavIrus vaccINatIoN ProgrammE IN fraNcE?
Yamin D.1, Remy V.2, Atkins K.E.1, Galvani A.P.1
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objeCtives: Rotavirus vaccines have shown great potential for reducing the 
disease burden of the major cause of severe childhood gastroenteritis. Real-life 
